Physician profile
Miranda Baumguardner
NPI 1730737214
$2,087.60
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,116 · 2022: $748 · 2023: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $280.59 | 2021-2022 | |
| Amgen INC. | $221.85 | 2021-2022 | |
| Abbvie INC. | $202.53 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.04 | 2021-2023 | Xifaxan |
| Potrero Medical, INC. | $110.74 | 2022 | |
| Abbott Laboratories | $107.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $100.57 | 2021 | |
| Boston Scientific Corporation | $62.78 | 2022 | |
| Glaxosmithkline, LLC. | $60.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $47.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.63 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.06 | 2021 | |
| Amarin Pharma, INC. | $26.17 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.33 | 2021 | |
| Eisai INC. | $23.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.93 | 2021 | |
| Lilly USA, LLC | $13.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Baumguardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.